Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | RBBP5 | Q15291 | 2/20 | 0.31 |
| ▸ | ASH2L | Q9UBL3 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CD44 | P16070 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27044682 | 0.74 | AR (0.35) | NOS3NOS1NOS2ALDH1A1MAPT | |
| SCHEMBL26890849 | 0.74 | POLB (0.31) | NOS3NOS1NOS2ALDH1A1MAPT | |
| SCHEMBL26884802 | 0.73 | AR (0.34) | — | |
| SCHEMBL26694576 | 0.72 | POLB (0.33) | WDR5ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL27044720 | 0.72 | AR (0.31) | — | |
| SCHEMBL26885127 | 0.71 | CD44 (0.31) | CD44 | |
| SCHEMBL23243523 | 0.70 | CYP3A4 (0.50) | WDR5KMT2ARBBP5ASH2L | |
| SCHEMBL31424206 | 0.70 | WDR5 (0.41) | WDR5KMT2ARBBP5ASH2L | |
| SCHEMBL26884943 | 0.70 | AR (0.35) | NOS3NOS1NOS2ALDH1A1MAPT | |
| SCHEMBL15556916 | 0.69 | HTT (0.39) | NOS3NOS1NOS2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | NOS3 4696/4885NOS1 4756/4885NOS2 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.